SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Who May Qualify: - Ability to understand and sign written willing to sign a consent form. - The diagnosis time of IPF before enrollment was less than 5 years. - Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF. - Dlco (corrected for Hb): 30%-90% predicted of normal. - FVC\>= 50% predicted of normal. Who Should NOT Join This Trial: - Forced expiratory volume in one second (FEV1)/FVC ratio \<0.7 after administration of bronchodilator at Screening - Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization. - Known explanation for interstitial lung disease - History of asthma or chronic obstructive pulmonary disease - Active infection - Ongoing IPF treatments including investigational therapy, immunosuppressants, and cytokine modulating agents - History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months Always talk to your doctor about whether this trial is right for you.